Provided by Tiger Trade Technology Pte. Ltd.

Oragenics

0.5250
-0.0150-2.78%
Post-market: 0.5191-0.0059-1.12%19:30 EDT
Volume:56.51K
Turnover:29.99K
Market Cap:2.37M
PE:-0.15
High:0.5449
Open:0.5312
Low:0.5200
Close:0.5400
52wk High:1.45
52wk Low:0.4801
Shares:4.51M
Float Shares:4.41M
Volume Ratio:1.04
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5875
EPS(LYR):-4.5629
ROE:-1307.06%
ROA:-171.49%
PB:0.65
PE(LYR):-0.12

Loading ...

Oragenics Inc - to Receive Exclusive License for Cardiodialysis for Tbi and Neurodegenerative Diseases - SEC Filing

THOMSON REUTERS
·
May 07

Oragenics signs LOI to license Sigyn CardioDialysis technology for TBI treatment

Reuters
·
May 07

Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.

Reuters
·
May 05

Oragenics activates second site for Phase IIa ONP-002 concussion trial in Australia

Reuters
·
May 05

Oragenics Inc: Phase Iia Clinical Data Readout Is Projected Before Year-End 2026

THOMSON REUTERS
·
May 05

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

TIPRANKS
·
Apr 20

Oragenics doses 2 patients in Phase IIa ONP-002 concussion trial

Reuters
·
Apr 20

Oragenics Reports 8 Study Drug Doses in Phase Iia Clinical Trial of Onp-002 for Mild Traumatic Brain Injury

THOMSON REUTERS
·
Apr 20

Oragenics doses first patient in Phase IIa ONP-002 concussion trial

Reuters
·
Apr 13

Oragenics Sets New 2025 Annual Shareholder Meeting Date

TIPRANKS
·
Apr 01

Oragenics changes annual shareholder meeting date to late June 2026

Reuters
·
Apr 01

Oragenics receives audit opinion with going concern explanation

TIPRANKS
·
Mar 26

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

GlobeNewswire
·
Mar 26

Oragenics files annual report on Form 10-K

TIPRANKS
·
Mar 17

Oragenics FY 2025 net loss narrows 6.86% to USD 9.84 million

Reuters
·
Mar 17

Oragenics completes first Phase IIa ONP-002 trial site initiation visit in Australia

Reuters
·
Mar 12

Oragenics Initiates Phase Iia Clinical Trial Site Activation

THOMSON REUTERS
·
Mar 12

Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions

TIPRANKS
·
Mar 12

Oragenics explores potential acquisition of additional assets in CNS space

TIPRANKS
·
Mar 11

Oragenics Explores Expansion of CNS Platform Pursuing Acquistion of Assets in Brain Health, Recovery, and Neuroprotection

THOMSON REUTERS
·
Mar 11